LIORESAL INTRATHECAL Rx
Generic Name and Formulations:
Baclofen 50mcg/mL, 500mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free.
Indications for LIORESAL INTRATHECAL:
Severe spasticity of cerebral or spinal origin, when oral baclofen is not appropriate.
Adults and Children:
<4yrs: not established. ≥4yrs: Give test dose 1st by intrathecal inj via spinal catheter or lumbar puncture (see full labeling for dose and timing; use 50mcg/mL syringe). Dose titration: see full labeling. Maintenance: titrate individually; use lowest effective dose; maintain muscle tone possibly close to normal. Spinal cord origin: usually 300–800mcg/day. Cerebral origin: usually 90–703mcg/day. Avoid abrupt cessation (may be severe/fatal); closely monitor pump, alarms, and refill schedule; wean orally-administered antispasticity drugs carefully.
Not for IV, IM, SC or epidural administration.
Do not discontinue abruptly; may result in high fever, altered mental status, rebound spasticity, muscle rigidity. Have resuscitative equipment and trained personnel available. Apparent risk patients (eg, spinal cord injury at T-6 or higher, communicative impairment, history of withdrawal symptoms): closely monitor infusion system, dosing schedule, refills, pump alarms, clinical signs of withdrawal or overdose. Do not use chronically if test dose ineffective. For chronic dosing use approved pump (eg, Medtronic SynchroMed Infusion System). Allow at least one year after traumatic brain injury before starting. Infections. Psychosis. Schizoaffective disorders. Confusion. Autonomic dysreflexia. Renal impairment. Hospitalize immediately if pump malfunction suspected. Pregnancy (Cat.C). Nursing mothers: not recommended.
Muscle relaxant (central), antispastic agent.
Hypotension, dyspnea with morphine. Additive CNS depression with alcohol, other CNS depressants. Do not mix with other drugs in pump or catheter.
Hypotonia, somnolence, dizziness, nausea, vomiting, paresthesia, headache, convulsion, hypotension, agitation, constipation, leukocytosis, chills, urinary retention, coma, drowsiness, psychosis, confusion; CNS depression, cardiovascular collapse, respiratory failure; others.
Single use ampules—1; Refill Kits—1, 2 (w. ampules and supplies)
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|